RPHM Key Statistics, Chart & Performance
The current stock price of RPHM is 1.82 USD. In the past month the price increased by 27.27%. In the past year, price decreased by -77.97%.
RPHM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About RPHM
Company Profile
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 8 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The firm's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The firm is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Company Info
RENEO PHARMACEUTICALS INC
18575 Jamboree Road, Suite 275-S
Irvine CALIFORNIA US
Employees: 8
Phone: 18582830280
RENEO PHARMACEUTICALS INC / RPHM FAQ
Can you describe the business of RENEO PHARMACEUTICALS INC?
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 8 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The firm's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The firm is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
What is the stock price of RENEO PHARMACEUTICALS INC today?
The current stock price of RPHM is 1.82 USD. The price increased by 5.2% in the last trading session.
Does RENEO PHARMACEUTICALS INC pay dividends?
RPHM does not pay a dividend.
How is the ChartMill rating for RENEO PHARMACEUTICALS INC?
RPHM has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for RPHM stock?
RENEO PHARMACEUTICALS INC (RPHM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.69).
What is the market capitalization of RPHM stock?
RENEO PHARMACEUTICALS INC (RPHM) has a market capitalization of 24.28M USD. This makes RPHM a Nano Cap stock.
RPHM Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to RPHM. When comparing the yearly performance of all stocks, RPHM is a bad performer in the overall market: 89.02% of all stocks are doing better.
RPHM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RPHM. No worries on liquidiy or solvency for RPHM as it has an excellent financial health rating, but there are worries on the profitability.
RPHM Financial Highlights
Over the last trailing twelve months RPHM reported a non-GAAP Earnings per Share(EPS) of -1.69. The EPS increased by 27.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.83% | ||
| ROE | -73.56% | ||
| Debt/Equity | 0 |
RPHM Forecast & Estimates
7 analysts have analysed RPHM and the average price target is 2.3 USD. This implies a price increase of 26.1% is expected in the next year compared to the current price of 1.82.